Although levels of those enzymes are elevated in 50% of patients with NAFL and in 80% of patients with NASH [15], studies have shown that tests for AST and ALT are not sensitive for predicting the severity of NAFLD [14]. The gene discussed is GPT; the disease is metabolic dysfunction-associated steatohepatitis.